Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC)
R. Gervais, A Ducoloné, Jean-Luc Breton et al. · Annals of Oncology · 2004
Cited by 116 works. doi:10.1093/annonc/mdi018
Authors
- R. Gervais
- A Ducoloné
- Jean-Luc Breton
- Denis Braun
- B Lebeau
- F. Vaylet
- Didier Debieuvre
- Jean Louis Pujol
- Jean Trédaniel
- P. Clouet
- Élisabeth Quoix
References
- Reporting results of cancer treatment
- Cancer incidence, mortality and prevalence worldwide
- Cancer Statistics, 2004
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
- Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
- Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
- American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
- Chemotherapy of Lung Cancer
- Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.